Zila Nutraceuticals
This article was originally published in The Tan Sheet
Executive Summary
Ronald Fugate named VP and general manager of Zila Nutraceuticals, Phoenix-based firm announces Sept. 18. Fugate brings experience from J&J, Kellogg Functional Foods Division to post; he most recently served as senior director-marketing at Bristol-Myers Squibb's Consumer Medicines division, where he led Pravachol Rx-to-OTC switch attempt (1"The Tan Sheet" July 24, 2000, p.12). In his new role, Fugate will look to introduce Zila's Ester-C vitamin C ingredient into new vitamin products. In a Sept. 18 conference call, Zila President & CEO Doug Burkett, PhD, said the firm expects to see 25% top line growth for Ester-C in 2002; ingredient recorded roughly $20 mil. in sales in 2001, firm says...
You may also be interested in...
OTC Statin Physician Follow-Up Label Comprehension Not Shown - FDA
Merck and Bristol Myers-Squibb should design label comprehension studies that do not assume consumers would understand how to use Mevacor and Pravachol in an OTC setting, FDA's Karen Lechter, PhD, advised during joint meetings of the Nonprescription and Endocrinologic & Metabolic Drugs Advisory Committees July 13-14.
Philips Portfolio Includes ‘No Single Product That Does Not Use A Type Of AI,’ Says CEO And AI Thought Leader Roy Jakobs
Philips CEO Roy Jakobs talks to Medtech Insight about the medtech firm’s decade-long history of embedding AI into its products and what he expects from the newly released draft framework by the National Academy of Medicine, which he helped develop as co-chair of the Steering Committee.
MoCRA Stakeholders Reminded Registration Enforcement Begins 1 July: ‘Do Not Delay!’
The Independent Beauty Association urged stakeholders at its Cosmetic Convergence Symposium to take action to ensure they are meeting requirements of the Modernization of Cosmetics Regulation Act come 1 July, when FDA’s enforcement of the facility and product registration deadline begins. Presenters offered tips from companies that have already completed the process.